ALSO NOTED: Dr. Reddy's buys small molecules biz; Labopharm appeals FDA decision; Avant touts typhoid fever data; and much more

> Dr. Reddy's has struck a deal to buy a portion of Dowharma's small molecules business in the UK. Report

> Labopharm has appealed the FDA's decision on its once-daily formulation of tramadol. Report

> Avant Immunotherapeutics says that an experimental typhoid fever vaccine--Ty800--met all primary endpoints in a mid-stage trial. Release

> Monogram Biosciences has inked a deal with Progenics Pharmaceuticals to provide resistance and tropism testing for Progenics' clinical development program of PRO 140, an investigational CCR5 monoclonal antibody being studied for HIV. Release

> VWR International has acquired the lab equipment supplier Jencons for an undisclosed sum. Report

> Here's a big strike against one strategy for protecting drug prices. A European Union advocate general said GlaxoSmithKline violated antitrust laws when it refused to fill Greek wholesalers' orders in a bid to prevent parallel importation. Report

> Did Amgen and Johnson & Johnson over-promote their anemia drugs? Congress is asking the companies for documents detailing their advertising and promotions, including a "bundling" discount Amgen allegedly offered to doctors on Neupogen and Neulasta in return for Aranesp scrips. Report

>  Mylan CEO and Vice Chairman Robert Coury (photo) brought down $10.3 million during fiscal 2007, which ran only nine months because the drugmaker changed its fiscal year. Report

> The Vytorin onslaught continues, with Congressional committees circling and secret emails surfacing. Report

And Finally… The largest survey ever of American physicians' opinions on healthcare financing has found that 59 percent of doctors support government legislation to establish national health insurance while only 32 percent oppose it. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.